Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature (Q39259095)

10 September 2017

title

Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature (English)

1 reference

10 September 2017

1 reference

Nishitha Thumallapally

1

1 reference

10 September 2017

Hana Yu

2

1 reference

10 September 2017

Mohammad Farhan

3

1 reference

10 September 2017

Uroosa Ibrahim

4

1 reference

10 September 2017

Maricel Odiami

5

1 reference

10 September 2017

publication date

1 January 2017

1 reference

Journal of Pharmacy Practice

10 September 2017

published in

1 reference

10 September 2017

page(s)

897190017704751

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

New and emerging targeted treatments in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Targeted therapies and immunotherapy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0897190017704751

21 January 2018

Identifiers

DOI

10.1177/0897190017704751

1 reference

10 September 2017

1 reference